z-logo
open-access-imgOpen Access
Clinical Features of Cutaneous Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cells Transplantation in Children with Hemato-Oncological Diseases
Author(s) -
Т. С. Белышева,
Т. З. Алиев,
Т. Т. Валиев,
Е. Б. Мачнева,
Н. В. Сидорова,
Н. Н. Мурашкин,
К. И. Киргизов,
С. Р. Варфоломеева
Publication year - 2020
Publication title -
voprosy sovremennoj pediatrii
Language(s) - English
Resource type - Journals
eISSN - 1682-5535
pISSN - 1682-5527
DOI - 10.15690/vsp.v19i6.2148
Subject(s) - medicine , hematopoietic stem cell transplantation , etiology , disease , transplantation , graft versus host disease , stem cell , pathogenesis , complication , immunology , dermatology , pathology , biology , genetics
The graft-versus-host disease (GvHD) is frequent complication, it occurs in 50% of patients after allogeneic hematopoietic stem cell transplantation (HSCT) and it is one of the major causes of mortality not associated with disease recurrence. Skin lesion in the symptom complex of acute GvHD develops within the first 100 days after HSCT, and it is complicated diagnostic and therapeutic problem. Significant immunosuppressive status of children during the posttransplant period enhances and changes the course of dermatoses, infections, drug toxicity. Finally, it can lead to immunoallergic processes with possible development to generalized life-threatening diseases of the skin and mucous membranes. Meanwhile, toxic, allergic and infectious skin lesions can be present simultaneously or develop sequentially. The description of the clinical picture of skin lesions in acute GvHD is really crucial and has scientific and practical significance due to relatively small frequency of HSCT in children with oncology diseases. The article summarizes data on etiology, pathogenesis, clinical forms, diagnostic and treatment methods of cutaneous complications of the early post-transplantation period after HSCT.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here